Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Total 13F shares
-
46,507,345
-
Share change
-
+7,358,816
-
Total reported value
-
$216,732,253
-
Put/Call ratio
-
40%
-
Price per share
-
$4.66
-
Number of holders
-
87
-
Value change
-
+$31,760,223
-
Number of buys
-
55
-
Number of sells
-
44
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q2 2024
As of 30 Jun 2024,
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,507,345 shares.
The largest 10 holders included
T. Rowe Price Investment Management, Inc., Bellevue Group AG, NEA Management Company, LLC, BlackRock Inc., VANGUARD GROUP INC, Vestal Point Capital, LP, TANG CAPITAL MANAGEMENT LLC, Artal Group S.A., MILLENNIUM MANAGEMENT LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
88
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.